Comprehensive detection area: covering coding and non-coding regions of BRCA gene mutation sites, including coding regions of BRCA1 and BRCA2 genes, exon intron junction regions, UTR regions, promoter regions, etc.

Applicable samples: Peripheral blood

BRCA1 and BRCA2 genes are important oncogenes that play a key role in DNA damage repair, and mutations in BRCA genes are closely related to the occurrence and progression of various tumors, including ovarian and breast cancers, etc. BRCA gene testing is recommended by the NCCN, CSCO, the American Society for Breast Surgery, and the Chinese Association for the Fight Against Cancer (CAC), and the results of the test can assist clinical decision-making on the selection of drugs, surgical protocols, and screening of at-risk populations, The results of the test can be used to assist clinical decision-making in drug selection, surgical plan, and screening of high-risk groups.

Female tumors seriously affect the physical and mental health of women in China, and the emergence of PARP inhibitors has opened up a new era of targeted therapy for ovarian cancer, breast cancer and other female tumors, among which, olaparib has been approved for the treatment of patients with ovarian cancer in China.Data from the SOLO1 clinical study announced at the ESMO Congress in 2018 showed that olaparib can significantly prolong BRCA mutation-positive ovarian cancer patients' disease progression-free survival. disease progression survival. According to the results of the clinical study reported in 2017 by NEJM, a leading professional journal, olaparib significantly prolonged disease progression-free survival in patients with BRCA mutation-positive, HER2-negative breast cancer. This provides a new option for some breast cancer patients who are difficult to treat with traditional modalities. In addition, PARP inhibitors have also shown significant efficacy in tumors such as fallopian tube cancer, prostate cancer, and pancreatic cancer.